Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Texas: - Houston Methodist San Jacinto Hospital — Baytown, Texas
- Houston Methodist Cypress Hospital — Cypress, Texas
- Dallas VA Medical Center — Dallas, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Ben Taub General Hospital — Houston, Texas
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Tarrant County Hospital District/JPS Health Network — Fort Worth, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Texas: - Covenant Medical Center-Lakeside — Lubbock, Texas
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in Texas: - Texas Oncology - Central/South Texas ( Site 8003) — Austin, Texas
- Cancer Clinics of North Texas ( Site 0077) — Dallas, Texas
- Texas Oncology - DFW ( Site 8001) — Dallas, Texas
- Texas Oncology - Gulf Coast ( Site 8002) — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Texas: - Urology Clinics of North Texas — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- MD Anderson Cancer Center — Houston, Texas
- Michael E DeBakey VA Medical Center — Houston, Texas
- Texas Oncology West Texas — Wichita Falls, Texas
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Texas: - USA Clinical Trials — San Antonio, Texas
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Texas: - Texas Oncology — Dallas, Texas
- Urology San Antonio — San Antonio, Texas
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Texas: - Urology Austin, PLLC - Research Department — Austin, Texas
- Urology Clinics of North Texas — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- The Urology Place — San Antonio, Texas
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Sites in Texas: - Texas Oncology South Austin — Austin, Texas
- Texas Oncology Gulf Coast — Houston, Texas
- Texas Oncology, P.A. - Tyler — Tyler, Texas
- Texas Oncology - West Texas — Wichita Falls, Texas
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Texas: - Michael E. DeBakey VA Medical Center, Houston, TX — Houston, Texas
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Sites in Texas: - Urology Clinics Of North Texas — Dallas, Texas
- Urology Partners of North Texas (UPNT) — Fort Worth, Texas
- Houston Metro Urology (HMU) — Houston, Texas
Phase 3 Recruiting Academic/Other
1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radia…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT06274047
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the im…
Sponsor: University of Alberta
NCT ID: NCT06626022
Sites in Texas: - UT Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
- South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Texas: - Research Site 135 — Austin, Texas
- Research Site 120 — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
- Oncology Consultants — Houston, Texas
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Texas: - MD Anderson The Woodlands — Conroe, Texas
- The University of Texas M. D. Anderson Cancer Center — Houston, Texas
- U.T. MD Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
- MD Anderson League City — League City, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Texas: - South Texas Accelerated Research Therapeutics — San Antonio, Texas
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Texas: - Research Site — Houston, Texas
Phase 2 Recruiting Federal
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…
Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Texas: - Michael E. DeBakey VA Medical Center, Houston, TX — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Texas: - NEXT Oncology — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main p…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT05125016
Sites in Texas: - MD Anderson Cancer Center — Houston, Texas